Seagen Says FDA Grants Priority Review For Supplemental Biologics License Application (SBLA) Of PADCEV (Enfortumab Vedotin-ejfv) With KEYTRUDA (Pembrolizumab) For First-Line Treatment Of Advanced Bladder Cancer
西根說,美國食品藥品管理局優先審查PADCEV(Enfortumab vedotin-ejfV)的補充生物製劑許可證申請(SBLA),使用KEYTRUDA(Pembrolizumab)對晚期膀胱癌進行一線治療